Published in Proc Natl Acad Sci U S A on December 19, 2003
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
Prostaglandins and cancer. Gut (2005) 3.44
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A (2004) 2.42
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest (2007) 1.89
Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech (2013) 1.55
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer (2007) 1.40
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res (2005) 1.36
Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol (2012) 1.27
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res (2006) 1.24
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev (2011) 1.21
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res (2005) 1.21
COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat (2011) 1.20
Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4. Am J Pathol (2009) 1.20
Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer (2006) 1.18
Lipid metabolic reprogramming in cancer cells. Oncogenesis (2016) 1.16
Mechanisms linking obesity and cancer. Biochim Biophys Acta (2013) 1.12
PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood (2011) 1.10
Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal (2007) 1.09
Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci U S A (2008) 1.09
Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One (2012) 1.07
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat (2008) 1.07
Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. Cancer Res (2010) 1.04
Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A (2004) 1.04
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Res (2013) 1.04
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J (2009) 1.02
The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol (2011) 1.00
The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev (2011) 0.99
The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids (2012) 0.98
Current evidence linking polyunsaturated Fatty acids with cancer risk and progression. Front Oncol (2013) 0.98
Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis. Invest Ophthalmol Vis Sci (2010) 0.97
Angiogenesis: a curse or cure? Postgrad Med J (2005) 0.97
Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis (2011) 0.96
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Integrin α3β1 as a breast cancer target. Expert Opin Ther Targets (2011) 0.93
Involvement of COX-2/PGE2 signalling in hypoxia-induced angiogenic response in endothelial cells. J Cell Mol Med (2012) 0.92
Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res (2010) 0.92
PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins Other Lipid Mediat (2008) 0.92
The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target. PLoS One (2012) 0.91
Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer (2009) 0.91
Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents. Biochim Biophys Acta (2008) 0.90
Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother (2009) 0.90
COX-2 in cancer: Gordian knot or Achilles heel? Front Pharmacol (2013) 0.89
Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer. Gastroenterol Res Pract (2011) 0.89
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Lett (2009) 0.89
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci (2014) 0.89
The role of ovarian sex steroids in metabolic homeostasis, obesity, and postmenopausal breast cancer: molecular mechanisms and therapeutic implications. Biomed Res Int (2015) 0.89
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res (2014) 0.88
Effect of 15-lipoxygenase metabolites on angiogenesis: 15(S)-HPETE is angiostatic and 15(S)-HETE is angiogenic. Inflamm Res (2012) 0.88
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila) (2008) 0.87
The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. Neoplasia (2008) 0.87
Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol (2013) 0.86
COX inhibitors directly alter gene expression: role in cancer prevention? Cancer Metastasis Rev (2011) 0.86
Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am J Pathol (2005) 0.85
CXCR4 in Cancer and Its Regulation by PPARgamma. PPAR Res (2008) 0.85
Exploiting the tumor microenvironment for theranostic imaging. NMR Biomed (2011) 0.85
Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases. Br J Cancer (2013) 0.84
Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo. J Biol Chem (2008) 0.84
The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells. Cancer Prev Res (Phila) (2009) 0.84
Physiological COX-2 expression in breast epithelium associates with COX-2 levels in ductal carcinoma in situ and invasive breast cancer in young women. Am J Pathol (2014) 0.83
Thalidomide-a notorious sedative to a wonder anticancer drug. Curr Med Chem (2013) 0.83
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br J Cancer (2014) 0.83
Lipid Signaling in Tumorigenesis. Mol Cell Pharmacol (2014) 0.82
Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation. Carcinogenesis (2012) 0.81
Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat (2013) 0.81
The role of morphine in animal models of human cancer: does morphine promote or inhibit the tumor growth? Biomed Res Int (2013) 0.81
Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis (2011) 0.80
Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment. J Bioanal Biomed (2011) 0.80
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J Cancer Res Clin Oncol (2013) 0.80
The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors. Mol Carcinog (2011) 0.80
miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget (2015) 0.80
Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer (2005) 0.79
COX-2 in liver, from regeneration to hepatocarcinogenesis: what we have learned from animal models? World J Gastroenterol (2010) 0.79
Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. J Mammary Gland Biol Neoplasia (2014) 0.79
Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract. Virchows Arch (2006) 0.79
Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands. Mol Carcinog (2011) 0.79
Up-regulation of cyclooxygenase-2-derived prostaglandin E(2) in colon cancer cells resistant to 5-fluorouracil. J Korean Surg Soc (2011) 0.78
Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice. Prostaglandins Other Lipid Mediat (2008) 0.78
Morphine Promotes Tumor Angiogenesis and Increases Breast Cancer Progression. Biomed Res Int (2015) 0.77
Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol (2015) 0.77
Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis. PLoS One (2012) 0.77
Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat (2014) 0.76
COX-2 dependent regulation of mechanotransduction in human breast cancer cells. Cancer Biol Ther (2015) 0.76
A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis. Oncotarget (2016) 0.76
Regulated expression of PTPRJ by COX-2/PGE2 axis in endothelial cells. PLoS One (2014) 0.75
Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation. World J Gastroenterol (2017) 0.75
Endogenous PGE(2) induces MCP-1 expression via EP4/p38 MAPK signaling in melanoma. Oncol Lett (2012) 0.75
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. BMC Cancer (2016) 0.75
Grape Seed Extract Attenuates Hepatitis C Virus Replication and Virus-Induced Inflammation. Front Pharmacol (2016) 0.75
Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget (2016) 0.75
Could Perioperative Opioid Use Increase the Risk of Cancer Progression and Metastases? Int Anesthesiol Clin (2016) 0.75
Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. Am J Cancer Res (2015) 0.75
Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. Oncotarget (2017) 0.75
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem (2000) 8.86
Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 7.46
Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest (2000) 5.48
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene (2000) 4.90
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res (2000) 4.18
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem (2001) 3.69
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med (2001) 2.98
Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst (1998) 2.26
Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med (2002) 2.17
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res (2000) 2.12
Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology (1996) 2.11
Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett (1995) 2.09
Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc Natl Acad Sci U S A (1993) 2.01
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res (2002) 2.00
Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol (1996) 1.97
Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol (2003) 1.95
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A (2002) 1.61
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res (1995) 1.48
Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science (1977) 1.21
Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol (1999) 1.19
Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res (1999) 1.14
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab (2003) 1.12
NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am (1996) 1.10
Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. J Clin Invest (1995) 1.08
Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer (1997) 1.06
Transcriptional regulation of vascular endothelial growth factor expression in epithelial and stromal cells during mouse mammary gland development. Mol Endocrinol (2001) 1.02
Liquid chromatographic-mass spectrometric determination of cyclooxygenase metabolites of arachidonic acid in cultured cells. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.00
Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation. Cancer Res (1976) 0.94
Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med (2003) 5.14
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev (2004) 4.41
Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med (2004) 4.34
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature (2008) 3.48
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem (2007) 3.07
S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol (2005) 2.98
Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem (2003) 2.98
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 2.97
Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal (2009) 2.92
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev (2002) 2.75
Structural and functional characteristics of S1P receptors. J Cell Biochem (2004) 2.75
FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant (2004) 2.70
Toll-like receptors induce a phagocytic gene program through p38. J Exp Med (2003) 2.49
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
Beta1 integrin establishes endothelial cell polarity and arteriolar lumen formation via a Par3-dependent mechanism. Dev Cell (2010) 2.25
Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice. J Clin Invest (2011) 2.23
VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn (2006) 2.21
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A (2011) 2.18
Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev (2004) 2.16
Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res (2004) 2.15
Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev Cell (2003) 2.15
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev (2010) 2.10
Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol (2006) 2.04
Role of spectral counting in quantitative proteomics. Expert Rev Proteomics (2010) 2.00
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res (2006) 1.98
Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem (2001) 1.97
Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J (2008) 1.96
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res (2006) 1.94
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol (2007) 1.91
Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest (2007) 1.89
Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res (2007) 1.77
Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med (2010) 1.73
Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta (2002) 1.72
Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J (2006) 1.72
Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat (2006) 1.68
PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A (2005) 1.67
Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest (2004) 1.67
Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem (2007) 1.66
Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem (2006) 1.63
Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell (2012) 1.62
Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum (2006) 1.59
Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. J Clin Invest (2009) 1.58
The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res (2005) 1.55
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res (2006) 1.55
PTH expands short-term murine hemopoietic stem cells through T cells. Blood (2012) 1.53
The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem (2003) 1.52
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res (2003) 1.50
Wnt signaling interacts with Shh to regulate taste papilla development. Proc Natl Acad Sci U S A (2007) 1.50
Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res (2011) 1.50
Wnt10b deficiency promotes coexpression of myogenic and adipogenic programs in myoblasts. Mol Biol Cell (2005) 1.47
TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol (2003) 1.46
Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. J Biol Chem (2007) 1.46
Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics (2007) 1.45
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol (2008) 1.44
Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol (2007) 1.41
Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol (2004) 1.40
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem (2007) 1.36
Absolute quantification of multisite phosphorylation by selective reaction monitoring mass spectrometry: determination of inhibitory phosphorylation status of cyclin-dependent kinases. Mol Cell Proteomics (2006) 1.36
Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat (2004) 1.35
Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol (2004) 1.35
Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol (2011) 1.34
The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res (2005) 1.33
T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab (2009) 1.32
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res (2005) 1.32
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol (2009) 1.32
Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev (2011) 1.29
Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res (2010) 1.29
Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res (2005) 1.28
A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev (2008) 1.27
Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol (2009) 1.26
Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol (2007) 1.24
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest (2015) 1.24
Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc Res (2009) 1.22
The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol (2003) 1.22
A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC). Prostaglandins Other Lipid Mediat (2007) 1.21
Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol (2004) 1.18
Proteomic mapping provides powerful insights into functional myelin biology. Proc Natl Acad Sci U S A (2004) 1.17
Lysophospholipid receptors in vertebrate development, physiology, and pathology. J Lipid Res (2008) 1.17
Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension (2004) 1.17
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med (2007) 1.16
Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression. J Biol Chem (2002) 1.15
Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.14
Sphingosine 1-phosphate signalling. Development (2014) 1.14
Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from monocytes/macrophage. Atherosclerosis (2002) 1.12
Global survey of human T leukemic cells by integrating proteomics and transcriptomics profiling. Mol Cell Proteomics (2007) 1.10
Systematic characterization of nuclear proteome during apoptosis: a quantitative proteomic study by differential extraction and stable isotope labeling. Mol Cell Proteomics (2006) 1.09
Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer (2008) 1.09
Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice. J Clin Invest (2008) 1.09
Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am J Physiol Heart Circ Physiol (2004) 1.08
Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics. Expert Rev Proteomics (2006) 1.08